Infections and Infectious Diseases

  • Home
  • Infections and Infectious Diseases
VRC 610: Phase I Safety and Pharmacokinetics Study to Evaluate a Human Monoclonal Antibody (MAB) VRC-HIVMAB095-00-AB (10E8VLS) Administered Alone or Concurrently With MAB VRC- HIVMAB075-00-AB (VRC07-523LS) Via Subcutaneous Injection in Healthy Adults

Condition:   Healthy Adult Immune Response
Interventions:   Biological: VRC-HIVMAB95-00-AB (10E8VLS);   Biological: VRC-MAB075-00-AB (VRC07-523LS)
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 21, 2018 / by / in
Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

Condition:   Infections, Bacterial
Intervention:   Drug: Gepotidacin
Sponsors:   GlaxoSmithKline;   Biomedical Advanced Research and Development Authority
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 20, 2018 / by / in
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile

Conditions:   Clostridium Difficile Infection Recurrence;   Clostridium Difficile Infection
Intervention:   Procedure: Fecal Microbiota Transplantation
Sponsor:   University of Massachusetts, Worcester
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 19, 2018 / by / in
Safety and Immunogenicity Study of an Influenza Vaccination Strategy Including an H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-18 Years Old

Conditions:   Influenza;   Influenza Immunisation
Interventions:   Biological: Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine;   Biological: Influenza Virus Quadrivalent Inactivated Vaccine;   Other: Placebo
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 12, 2018 / by / in
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Condition:   Chikungunya Virus Infection
Interventions:   Biological: CHIKV VLP/unadjuvanted;   Biological: CHIKV VLP/adjuvanted;   Biological: Placebo
Sponsor:   PaxVax, Inc.
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 10, 2018 / by / in
Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Conditions:   HIV/AIDS;   HIV-1-infection;   Osteopenia
Interventions:   Drug: Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC);   Drug: Current tenofovir alafenamide (TAF)-containing ART regimen
Sponsor:   Philip Grant
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 9, 2018 / by / in
Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

Condition:   Pneumococcal Infections
Interventions:   Biological: Multivalent;   Biological: Prevnar 13
Sponsor:   Pfizer
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 8, 2018 / by / in
Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

Condition:   Chronic Granulomatous Disease
Intervention:   Drug: Interferon Gamma-1B
Sponsor:   University of Colorado, Denver
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 7, 2018 / by / in
Microbial Restoration for Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)

Conditions:   Clostridial Infection;   Dysbacteriosis;   Probiotic Therapy
Interventions:   Procedure: Fecal Microbiota Transplantation (FMT);   Drug: Saline
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 6, 2018 / by / in